AUS
NZ
UK
CA
USA
IND
Highlights
- Lumos Diagnostics partners with MedPro Associates to expand FebriDx sales reach.
- The partnership aims to boost FebriDx's adoption by covering diverse healthcare markets in the US.
- Ongoing CLIA waiver study set to simplify the use of FebriDx in non-lab settings.
Lumos Diagnostics (ASX:LDX) has entered a strategic partnership with MedPro Associates, aiming to significantly expand the national sales coverage of its innovative FebriDx test across various healthcare sectors in the United States. This initiative is designed to improve the adoption and accessibility of FebriDx, a rapid point-of-care (POC) test that differentiates between bacterial and non-bacterial acute respiratory infections.
Partnership Overview
The collaboration taps into MedPro's extensive network, leveraging over 60 territory representatives strategically positioned nationwide to enhance market penetration and product awareness. MedPro's engagement will extend across health systems, government entities, and private physician offices, acting as an extension of Lumos’ sales force. This arrangement includes customer lead generation, sales revenue facilitation, and comprehensive customer training for the FebriDx test.
Strategic Impact
This partnership is poised to make a substantial impact on Lumos Diagnostics' presence in the US market. MedPro’s expertise spans both acute care environments - such as hospitals and federal institutions - and non-acute settings including physician offices and skilled nursing facilities. Their deep-rooted relationships with key decision-makers will be pivotal in driving product conversions that enhance patient care.
CLIA Waiver Study
In tandem with these efforts, Lumos has commenced a critical CLIA waiver study for FebriDx in the US. This study involves testing the device in non-laboratory settings and is instrumental in redefining its application parameters. Supported by a substantial grant from the Biomedical Advanced Research and Development Authority (BARDA), the study will aim to enroll between 500 and 800 patients to achieve conclusive insights, meriting a reclassification of FebriDx from moderate complexity to a CLIA-waived device.
Addressing Antibiotic Overuse
FebriDx offers a unique solution addressing the alarming trend of antibiotic overprescription for viral infections, which constitute the majority of acute respiratory cases. The capability of the FebriDx test to accurately discern the nature of infections supports better-informed treatment decisions, contributing to the reduction of antibiotic resistance – a significant health challenge impacting millions of Americans.
Leadership Insights
Leaders from Lumos and MedPro have expressed their enthusiasm for this partnership. MedPro's CEO, Bill Sparks, underscored the accelerated diagnostics potential and improved patient care expected through their collaboration, while Lumos CEO Doug Ward emphasized the alignment of MedPro’s market proficiency and client relationship strengths with Lumos’ strategic goals.
